EGFR and colorectal cancer: (45) explored clonal evolution in colorectal cancer patients undergoing treatment, demonstrating that resistant subpopulations emerge under therapeutic pressure, particularly in response to EGFR inhibitors and oxaliplatin-based chemotherapy.